On July 28, 2020, TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $15.50 per share. TCR2 also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by the company, are expected to be $124 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by TCR2. The offering is expected to close on or about July 31, 2020, subject to customary closing conditions. TCR2 intends to use the net proceeds of the offering to advance its clinical and earlier stage programs and for research and development, working capital, and general corporate purposes.

The Wilson Sonsini Goodrich & Rosati team that advised TCR2 Therapeutics on all IP matters related to the offering includes Mike Hostetler, Louis Lieto, Chris McAndrew, and Mengmeng Zhang.

For more information, please see TCR2's press release.